KRAS and cancer: Oncogenes activation (e.g., c-MYC and KRAS) and tumor suppressor genes inactivation (e.g., TP53) in cancer cells increase the translocation of glucose transporters on plasma membrane and up-regulate the glucose intake and the glycolytic rate [32,33,34].